Answers are grounded in this paper and cite their sources.
Open-label Phase III study finds canakinumab improves outcomes in Japanese patients with AOSD, indicating potential benefits.
Although the primary endpoint was not met, week 28 analysis showed that canakinumab treatment led to improvements in various efficacy outcome measures in Japanese patients with AOSD, with no unexpected safety signals.
No takes yet. Share an insight, caveat, or question.
Atsumi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: